TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33183170

Group type: EXPERIMENTAL
Intervention: Educational intervention based on the theory of planned behavior
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (non-training)
Number of subjects: 140
Study: 32281915

Group type: EXPERIMENTAL
Intervention: HMB (1.5g per day for 2 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study: 36371148

Group type: EXPERIMENTAL
Intervention: PEEP10
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PEEP5
Number of subjects: 120

Group type: COMPARATOR
Intervention: PEEP0
Number of subjects: 120
Study: 33002427

Group type: EXPERIMENTAL
Intervention: Nebulised ALX‐0171 3 mg/kg
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Nebulised ALX‐0171 6 mg/kg
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Nebulised ALX‐0171 9 mg/kg
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: All ALX‐0171 groups
Number of subjects: 175
Study: 36260394

Group type: EXPERIMENTAL
Intervention: mHealth behavior change intervention with a 4-hour tailored lifestyle education session and personalized goal setting
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: mHealth behavior change intervention
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 123
Study: 32221987

Group type: EXPERIMENTAL
Intervention: Brivaracetam at individualized doses ≤200 mg/d
Number of subjects: 667
Study: 36432445

Group type: EXPERIMENTAL
Intervention: Concentrated beetroot juice (140 mL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-nitrate control supplement
Number of subjects: 18
Study: 34768404

Group type: EXPERIMENTAL
Intervention: Albumin (1.5 g/kg at baseline and 1 g/kg on day 3)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 82
Study: 35303460

Group type: EXPERIMENTAL
Intervention: Community-based programme for corneal ulcer prevention involving training of female community health volunteers (FCHVs) to diagnose corneal abrasions and provide a 3-day course of ophthalmic antimicrobials.
Number of subjects: 252539

Group type: COMPARATOR
Intervention: Control group with no intervention provided by FCHVs.
Number of subjects: 252539
Study: 33152277

Group type: EXPERIMENTAL
Intervention: IM‐MS irradiation at 50 Gy in 25 fractions
Number of subjects: 4004

Group type: COMPARATOR
Intervention: No IM‐MS irradiation (control group)
Number of subjects: 4004
Study: 36041466

Group type: EXPERIMENTAL
Intervention: Disclosure of stuttering
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Low communication competence with disclosure
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: High communication competence
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Combination of self-disclosure and high communication competence
Number of subjects: 238
Study: 33306991

Group type: EXPERIMENTAL
Intervention: 2 μg ID93 + 5 μg GLA‐SE on days 0 and 56
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 2 μg ID93 + 5 μg GLA‐SE on days 0, 28, and 56
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 35648041

Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone (Ld arm)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Autologous stem cell transplantation (ASCT) (Ld + ASCT arm)
Number of subjects: 65
Study: 33413345

Group type: EXPERIMENTAL
Intervention: Apabetalone
Number of subjects: 2425
Study: 32068895

Group type: EXPERIMENTAL
Intervention: Distress tolerance in schizophrenia
Number of subjects: 87

Group type: COMPARATOR
Intervention: Distress tolerance in borderline personality disorder (BPD)
Number of subjects: 87
Study: 35114131

Group type: EXPERIMENTAL
Intervention: 177Lu‐Dotatate plus long‐acting octreotide
Number of subjects: 117

Group type: COMPARATOR
Intervention: High‐dose long‐acting octreotide
Number of subjects: 117
Study: 34347216

Group type: EXPERIMENTAL
Intervention: PRP + IVR
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PIR + IVR
Number of subjects: 28
Study: 35222756

Group type: EXPERIMENTAL
Intervention: IntellaTip MiFi catheter using ME signals alone
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard 8 mm non-irrigated catheter with bipolar signals
Number of subjects: 61
Study: 33275151

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: PVI plus complex fractionated electrograms
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: PVI plus linear lesions
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: No recurrence of AF
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Recurrence of AF
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: AF burden reduction
Number of subjects: 549
Study: 35680270

Group type: EXPERIMENTAL
Intervention: Community organisation targeted multicomponent education and training initiative on CPR and OHCA over 12 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Delayed programme implementation (Control)
Number of subjects: 200
Study: 34004400

Group type: EXPERIMENTAL
Intervention: Practical Resources for Effective Postpartum Parenting (PREPP)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 109
Study: 32891560

Group type: EXPERIMENTAL
Intervention: Labia minora and clitoral hood creation (group A)
Number of subjects: 167

Group type: COMPARATOR
Intervention: No labia minora and clitoral hood creation (group B)
Number of subjects: 167
Study: 34636086

Group type: EXPERIMENTAL
Intervention: MiQuit (12 weeks of tailored, smoking cessation text messages)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: MiQuit
Number of subjects: 1002

Group type: COMPARATOR
Intervention: MiQuit and UC (TSA meta-analysis)
Number of subjects: 1002
Study: 33831909

Group type: EXPERIMENTAL
Intervention: Switching to a single-tablet regimen of cobicistat, elvitregravir, emtricitabine along with tenofovir alafenamide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Two-drug regimen based on dolutegravir and one reverse transcriptase inhibitor (RTI)
Number of subjects: 50
Study: 36687270

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 55

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 55

Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 55
Study: 33428320

Group type: EXPERIMENTAL
Intervention: Pelvic floor physiotherapy (PFP), 5 individual sessions
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pelvic floor physiotherapy (PFP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study: 33951066

Group type: EXPERIMENTAL
Intervention: Participants from African regions
Number of subjects: 289

Group type: COMPARATOR
Intervention: Participants from non-African regions
Number of subjects: 289
Study: 33378824

Group type: EXPERIMENTAL
Intervention: Quantitative fecal immunochemical test (FIT) at a cutoff value of 20 μg Hb/g
Number of subjects: 3407

Group type: EXPERIMENTAL
Intervention: Quantitative fecal immunochemical test (FIT) at a decreased cutoff value of 5 μg Hb/g
Number of subjects: 3407

Group type: EXPERIMENTAL
Intervention: Quantitative fecal immunochemical test (FIT)
Number of subjects: 3407
Study: 36477547

Group type: EXPERIMENTAL
Intervention: Mass azithromycin distributions
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatments (control group)
Number of subjects: 60
Study: 34236782

Group type: EXPERIMENTAL
Intervention: Prolonged mechanical ventilation (PMV) group (group 2 >24 hours)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Prolonged mechanical ventilation (PMV)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Early extubation group (group 1 <24 hours)
Number of subjects: 207
Study: 34319926

Group type: EXPERIMENTAL
Intervention: Induction rabbit antithymocyte globulin (rATG) with delayed CNI initiation (day 10)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard of care (upfront CNI commencement)
Number of subjects: 110
Study: 34783726

Group type: EXPERIMENTAL
Intervention: Tibiofemoral joint mobilisation in addition to 6 stretching and strengthening exercises of hip and knee muscles with hot pack (Group B)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 6 stretching and strengthening exercises of hip and knee muscles with hot pack (Group A)
Number of subjects: 52
Study: 32270926

Group type: EXPERIMENTAL
Intervention: Fenebrutinib 50 mg once daily
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Fenebrutinib 150 mg once daily
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Fenebrutinib 200 mg twice daily
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Fenebrutinib 200 mg twice daily (cohort 2)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 578
Study: 34793986

Group type: EXPERIMENTAL
Intervention: Revascularization with stenting
Number of subjects: 879

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy (SET) plus OMT
Number of subjects: 879

Group type: COMPARATOR
Intervention: Real-world cohort (PORTRAIT registry)
Number of subjects: 879
Study: 36329596

Group type: EXPERIMENTAL
Intervention: Esmolamine (0.1mg/kg intravenous injection 10 min before induction, followed by 2 μg•kg‐1•min‐1 infusion)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline infusion (control group)
Number of subjects: 100
Study: 32330272

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34538227

Group type: EXPERIMENTAL
Intervention: five-flash intense pulsed light therapy (IPL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: conventional home care alone
Number of subjects: 100
Study: 34549388

Group type: EXPERIMENTAL
Intervention: Single intravenous doses of S-oxiracetam (S-ORT) at 2.0 g, 4.0 g, and 8.0 g
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of 3.0 g S-ORT
Number of subjects: 52

Group type: COMPARATOR
Intervention: Single intravenous infusion of 6.0 g racemic oxiracetam (R-ORT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Daily intravenous injection of 4.0 g S-ORT for 7 days
Number of subjects: 52
Study: 35331002

Group type: EXPERIMENTAL
Intervention: Steerable ureteroscopic renal evacuation (SURE)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Basket extraction
Number of subjects: 17
Study: 34810345

Group type: EXPERIMENTAL
Intervention: Probiotic formulation applied for 6 consecutive days
Number of subjects: 10
Study: 32143570

Group type: EXPERIMENTAL
Intervention: Paravertebral block combined with general anesthesia (PVB/GA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 54
Study: 36228640

Group type: EXPERIMENTAL
Intervention: Daily contact testing (DCT) with seven lateral flow device (LFD) tests and two PCR tests, no isolation if negative on LFD.
Number of subjects: 54923

Group type: COMPARATOR
Intervention: Self-isolation with a single PCR test and 10-day isolation.
Number of subjects: 54923

Group type: COMPARATOR
Intervention: Comparison of DCT and self-isolation.
Number of subjects: 54923
Study: 33826691

Group type: EXPERIMENTAL
Intervention: MED0.5 (0.5 oz lean beef)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: MED2.5 (2.5 oz lean beef)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: MED5.5 (5.5 oz lean beef)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Average American Diet (AAD)
Number of subjects: 59
Study: 35417909

Group type: EXPERIMENTAL
Intervention: Once-weekly somatrogon (0.25, 0.48, and 0.66 mg/kg/week for 12 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Once-daily Genotropin (0.025 mg/kg/day for 12 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison of somatrogon to Genotropin
Number of subjects: 44
Study: 33588138

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.4 ml/mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Long-acting betamethasone (0.1 ml/mg)
Number of subjects: 31
Study: 36412293

Group type: EXPERIMENTAL
Intervention: Intraosseous anesthesia (IOA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Needle-free dental anesthesia (NFA)
Number of subjects: 20
Study: 32621599

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate (CHX) 2% for 30s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaClO) 1% for 30s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaClO) 2.5% for 30s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaClO) 1% for 1min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaClO) 2.5% for 1min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate (CHX) 2% for 1min
Number of subjects: 0
Study: 36330832

Group type: EXPERIMENTAL
Intervention: Integrative adapt therapy (IAT)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 327
Study: 33030089

Group type: EXPERIMENTAL
Intervention: Propranolol 60 mg twice daily
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 143
Study: 32785749

Group type: EXPERIMENTAL
Intervention: 3-month follow-up interval
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6-month follow-up interval
Number of subjects: 20
Study: 32310040

Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulants
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dual-drug approach with LMWH-VKA
Number of subjects: 12
Study: 33054386

Group type: EXPERIMENTAL
Intervention: FOCAL training program
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo training program
Number of subjects: 36
Study: 34858915

Group type: EXPERIMENTAL
Intervention: Exposure to alpha‐diketones and other VOCs
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Medical evaluations including questionnaire, spirometry, impulse oscillometry, and fractional exhaled nitric oxide
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Engineering controls evaluation
Number of subjects: 17
Study: 33141843

Group type: EXPERIMENTAL
Intervention: Hemoadsorption
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no hemoadsorption)
Number of subjects: 72
Study: 36286945

Group type: EXPERIMENTAL
Intervention: Aterixen (100 mg tablets)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 34025069

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (wait-and-see approach)
Number of subjects: 0
Study: 34351728

Group type: EXPERIMENTAL
Intervention: FAST repetition tempo (1-0-1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: SLOW repetition tempo (1-0-3)
Number of subjects: 13
Study: 33440985

Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA) applied on four points: shemen, liver, spleen, and finger/toe, thrice daily for 3 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham auricular acupressure applied on four remote points unrelated to neuropathic symptoms, thrice daily for 3 weeks
Number of subjects: 120
Study: 35328876

Group type: EXPERIMENTAL
Intervention: Physical activity home practice and exercise classes
Number of subjects: 589

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 589
Study: 35718794

Group type: EXPERIMENTAL
Intervention: D‐SCAN intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 34107141

Group type: EXPERIMENTAL
Intervention: Spirulina supplementation (1 g/day, two 500 mg capsules)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 33320461

Group type: EXPERIMENTAL
Intervention: Dried figs
Number of subjects: 99

Group type: COMPARATOR
Intervention: Cinnamon
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 34358773

Group type: EXPERIMENTAL
Intervention: Sound-field amplification (SFA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No sound-field amplification (no SFA)
Number of subjects: 30
Study: 34972808

Group type: EXPERIMENTAL
Intervention: Non-speculum clinician-taken sampling and self-sampling
Number of subjects: 784

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 784
Study: 34120329

Group type: EXPERIMENTAL
Intervention: Highest quartile of Dietary Phytochemical Index (DPI)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Highest quartile of Dietary Phytochemical Index (DPI) after adjustment for potential confounders
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Highest quartile of Dietary Phytochemical Index (DPI) after further adjustment for BMI
Number of subjects: 350
Study: 32143961

Group type: EXPERIMENTAL
Intervention: Tearscope Plus (TS)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Polaris (POL)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: EasyTear Viewplus (ET)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Keratograph 5 M (KER)
Number of subjects: 72

Group type: COMPARATOR
Intervention: All instruments (TS, POL, ET, KER)
Number of subjects: 72
Study: 36104813

Group type: EXPERIMENTAL
Intervention: HEAT intervention (participatory heat education and supervisor decision-support mobile application)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Comparison group (alternative-training)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 75
Study: 34688304

Group type: EXPERIMENTAL
Intervention: Public contributor involvement in trial teams
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Public contributor payment
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Training for public contributors
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tasks undertaken by public contributors
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Feedback on public contributor input
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Barriers to successful PPI
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Successful PPI requirements
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CTU's role in PPI
Number of subjects: 21
Study: 32579807

Group type: EXPERIMENTAL
Intervention: 320 μg budesonide, 18 μg glycopyrrolate, 9.6 μg formoterol (triple therapy)
Number of subjects: 8509

Group type: EXPERIMENTAL
Intervention: 160 μg budesonide, 18 μg glycopyrrolate, 9.6 μg formoterol (triple therapy)
Number of subjects: 8509

Group type: COMPARATOR
Intervention: 18 μg glycopyrrolate, 9.6 μg formoterol (dual therapy)
Number of subjects: 8509

Group type: COMPARATOR
Intervention: 320 μg budesonide, 9.6 μg formoterol (dual therapy)
Number of subjects: 8509
Study: 35210467

Group type: EXPERIMENTAL
Intervention: Active-MTrP-DDN
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Latent-MTrP-DDN
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-MTrP-DDN
Number of subjects: 65
Study: 32437937

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) testing
Number of subjects: 773

Group type: COMPARATOR
Intervention: Antibiotic prescription
Number of subjects: 773
Study: 32945066

Group type: EXPERIMENTAL
Intervention: 30-g fecal microbiota transplantation (FMT)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 60-g fecal microbiota transplantation (FMT)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo (own feces)
Number of subjects: 142
Study: 32203968

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU weekly for 9 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 88
Study: 35986239

Group type: EXPERIMENTAL
Intervention: Individualized treatment strategy based on preoperative risk score
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (no individualized prevention)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Individualized treatment strategy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study: 33484381

Group type: EXPERIMENTAL
Intervention: Stem cell therapy
Number of subjects: 3142

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 3142
Study: 32245060

Group type: EXPERIMENTAL
Intervention: Educational intervention including professional skills training sessions and team communication.
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group following the routine work plan.
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Educational intervention.
Number of subjects: 241
Study: 35333352

Group type: EXPERIMENTAL
Intervention: Intensive breast milk nutritional support program (IBNSP) with breastfeeding, administered for the first 48 hours after birth, including face-to-face training and practical support.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intensive breast milk nutritional support program (IBNSP) with breastfeeding.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard care recommended by the World Health Organization (Control group).
Number of subjects: 68
Study: 34213672

Group type: EXPERIMENTAL
Intervention: Genicular nerve block (GNB)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Intra-articular triamcinolone
Number of subjects: 64
Study: 33370134

Group type: EXPERIMENTAL
Intervention: Body Project intervention (peer-delivered)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 112
Study: 34802302

Group type: EXPERIMENTAL
Intervention: Play Nicely online program (n = 21)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control condition website (n = 31)
Number of subjects: 52
Study: 32149773

Group type: EXPERIMENTAL
Intervention: Methylprednisolone via intravenous injection at a dose of 1-2 mg/kg/day for 3 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: No glucocorticoid use (Control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 48
Study: 36003030

Group type: EXPERIMENTAL
Intervention: Instrumental reminiscence therapy based on Roy's adaptation model
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study: 34146513

Group type: EXPERIMENTAL
Intervention: ICP monitoring
Number of subjects: 2395